Ovid Therapeutics
OVID
81 hedge funds and large institutions have $153M invested in Ovid Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 8 closing their positions.
2,700% more call options, than puts
Call options by funds: $28K | Put options by funds: $1K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
22% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 23
5% more funds holding
Funds holding: 77 → 81 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.41% less ownership
Funds ownership: 73.28% → 70.87% (-2.4%)
8% less capital invested
Capital invested by funds: $167M → $153M (-$13.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$3.29M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$746K |
| 3 |
Millennium Management
New York
|
+$488K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$456K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$385K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$10M |
| 2 |
Morgan Stanley
New York
|
-$562K |
| 3 |
BlackRock
New York
|
-$417K |
| 4 |
VPC
Vestal Point Capital
New York
|
-$275K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$273K |
OVID Hedge Fund Activity: Q1 2024 in Review
81 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2024, worth a combined $153M — down 8.4% from $167M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new OVID positions and 8 closed out — a net gain of 4 holders — while 28 added to existing stakes and 23 trimmed.
The largest buyer was Prosight Management, opening a new position worth an estimated $3.29M. The largest seller was BVF Inc, cutting an estimated $10M.
- 81 institutional investors held Ovid Therapeutics (OVID) as of Q1 2024, up from 77 in Q4 2023.
- Funds reported $153M of Ovid Therapeutics stock for Q1 2024, down 8.4% quarter-over-quarter.
- 12 funds opened new Ovid Therapeutics positions in Q1 2024 and 8 closed out, a net change of +4 holders.
- The largest Ovid Therapeutics buyer in Q1 2024 was Prosight Management, an estimated $3.29M added.
- The largest Ovid Therapeutics seller in Q1 2024 was BVF Inc, an estimated $10M sold.
Based on aggregated 13F filings for Q1 2024.